Myocardial Oedema in Acute Myocardial Infarction (AMI)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00987259 |
Recruitment Status :
Completed
First Posted : September 30, 2009
Last Update Posted : February 1, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Despite recent improvements in treatment, myocardial infarction (heart attack) is still a leading cause of illness and death in the UK. Following the acute event, it is difficult to predict which patients are at risk of further problems, such as heart failure and is therefore difficult to know which patients need more aggressive/intensive treatment and monitoring.
There needs to be a test which is safe, reliable and reproducible that can be used shortly after a heart attack to both predict future cardiac events and to allow the efficacy of new treatments to be assessed.
Myocardial oedema (swelling of the heart muscle) has been demonstrated using Cardiac Magnetic Resonance (CMR), to occur following a heart attack and has been suggested as a marker for future cardiac events. The optimum time to perform this scan, the method of data analysis and it's effectiveness as a predictor of future cardiac events has not been adequately assessed.
This trial will assess the amount and natural time-course of oedema in the first 10 days following a heart attack. It will also correlate the amount of oedema with the size of scar (damaged heart muscle) and left ventricular ejection fraction (heart function) at 3 months to assess if it is a predictive marker.
Condition or disease |
---|
Myocardial Infarction |
Study Type : | Observational |
Actual Enrollment : | 20 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Determination of the Time Course of Myocardial Oedema Post Myocardial Infarction Treated With Primary Angioplasty Using Cardiac Magnetic Resonance Imaging |
Study Start Date : | November 2009 |
Actual Primary Completion Date : | June 2011 |
Actual Study Completion Date : | October 2011 |
Group/Cohort |
---|
Post MI patients
Patients recruited following a successfully reperfused myocardial infarction using primary angioplasty.
|
- Extent and time course of myocardial oedema over the first 10 days post MI [ Time Frame: Days 1, 3 and 10 post MI ]
- Left ventricular ejection fraction and left ventricular scar size at 3 months [ Time Frame: 90 days post MI ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients presenting to the London Chest Hospital with acute ST elevation myocardial infarction and treated with primary angioplasty and stent implantation within 12 hours of symptom onset
- Acute PCI / stent implantation has been successful (residual stenosis visually < 30% and TIMI flow ≥ 2)
- At the time of inclusion, the patient no longer requires intravenous catecholamines or mechanical hemodynamic support (aortic balloon pump)
- Serum troponin >1ng/ml 12 hours after onset of pain
- The patient is able to give written informed consent
- The patient must be able to understand and communicate in English
Exclusion Criteria:
- Known cardiomyopathy
- Previous documented myocardial infarction
- Previous percutaneous coronary intervention or coronary artery bypass surgery
- Significant renal dysfunction (EGFR<30)
- Systemic steroid therapy
- Current non steroidal anti-inflammatory drug use
- Chronic inflammatory disease
- Neoplastic disease without documented remission within the past 5 years
- Pregnancy
- Reduced mental capacity leading to inability to obtain informed consent
- Participation in another clinical trial within the last 30 days
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00987259
United Kingdom | |
The London Chest Hospital | |
London, Greater London, United Kingdom, E2 9JX |
Principal Investigator: | Thomas R Burchell, BSc, MB BS | Bart's and The London NHS Trust, United Kingdom |
Responsible Party: | Barts & The London NHS Trust |
ClinicalTrials.gov Identifier: | NCT00987259 |
Other Study ID Numbers: |
BLT006964 |
First Posted: | September 30, 2009 Key Record Dates |
Last Update Posted: | February 1, 2013 |
Last Verified: | September 2009 |
Myocardial infarction Myocardial oedema Magnetic resonance |
Myocardial Infarction Infarction Ischemia Pathologic Processes Necrosis |
Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases |